Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuang Yu

Showing results (571-580 of 598) with videos related to

Pageof 60
Sort By:
Ageing Research Reviews|December 8, 2023
Modulating the polarization phenotype of microglia - A valuable strategy for central nervous system diseasesYu Long, Xiao-Qiu Li, Jie Deng, et al.
Cell|August 13, 2019
GDF15 Is an Inflammation-Induced Central Mediator of Tissue ToleranceHarding H Luan, Andrew Wang, Brandon K Hilliard, et al.
Expert Opinion on Investigational Drugs|February 9, 2023
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjectsYanli Wang, Jinling Xue, Zhengjie Su, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 12, 2022
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjectsZhengzhi Liu, Zhenyue Gao, Wei Yang, et al.
Journal of Parkinson'S Disease|October 3, 2025
A longitudinal study on physical activity in early Parkinson's diseaseSamuel Yong-Ern Ng, Darakhshan Naheed, Ehsan Seyed Saffari, et al.
Expert Review of Clinical Pharmacology|March 8, 2023
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trialZhongnan Xu, Zhengzhi Liu, Yanli Wang, et al.
Oncogene|October 17, 2022
Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capabilityShubin Hong, Yubin Xie, Zhen Cheng, et al.
International Immunopharmacology|April 23, 2022
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Zhengzhi Liu, et al.
Oncogene|March 13, 2022
Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancerShuang Yu, Changan Liu, Yingtong Hou, et al.
Journal of Parkinson'S Disease|February 6, 2023
Microstructure of Brain Nuclei in Early Parkinson's Disease: Longitudinal Diffusion Kurtosis ImagingThomas Welton, Septian Hartono, Yao-Chia Shih, et al.
Pageof 60

Showing results (571-580 of 598) with videos related to

Sort By:
Pageof 60
Ageing Research Reviews|December 8, 2023
Modulating the polarization phenotype of microglia - A valuable strategy for central nervous system diseasesYu Long, Xiao-Qiu Li, Jie Deng, et al.
Cell|August 13, 2019
GDF15 Is an Inflammation-Induced Central Mediator of Tissue ToleranceHarding H Luan, Andrew Wang, Brandon K Hilliard, et al.
Expert Opinion on Investigational Drugs|February 9, 2023
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjectsYanli Wang, Jinling Xue, Zhengjie Su, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 12, 2022
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjectsZhengzhi Liu, Zhenyue Gao, Wei Yang, et al.
Journal of Parkinson'S Disease|October 3, 2025
A longitudinal study on physical activity in early Parkinson's diseaseSamuel Yong-Ern Ng, Darakhshan Naheed, Ehsan Seyed Saffari, et al.
Expert Review of Clinical Pharmacology|March 8, 2023
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trialZhongnan Xu, Zhengzhi Liu, Yanli Wang, et al.
Oncogene|October 17, 2022
Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capabilityShubin Hong, Yubin Xie, Zhen Cheng, et al.
International Immunopharmacology|April 23, 2022
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Zhengzhi Liu, et al.
Oncogene|March 13, 2022
Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancerShuang Yu, Changan Liu, Yingtong Hou, et al.
Journal of Parkinson'S Disease|February 6, 2023
Microstructure of Brain Nuclei in Early Parkinson's Disease: Longitudinal Diffusion Kurtosis ImagingThomas Welton, Septian Hartono, Yao-Chia Shih, et al.
Pageof 60